Treatment implications for radiation-induced nausea and vomiting in specific patient groups

European Journal of Cancer

Volumn 40, Issue 7, 2004, Pages 979-987

  Horiot, J C ^a   Aapro, M ^b  

^a Ctr Lutte Contre Cancer Georges F   (France)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Antiemetic; Drug interactions; Granisetron; Nausea; Ondansetron; Radiochemotherapy; Radiotherapy; RINV; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON; RIFAMPICIN; SEROTONIN 1 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TROPISETRON;

ANGINA PECTORIS; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; FATIGUE; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER DISEASE; NAUSEA; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; TACHYCARDIA; TORSADE DES POINTES; VOMITING;

AGE FACTORS; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSTIPATION; DRUG INTERACTIONS; FATIGUE; HEART DISEASES; HUMANS; NAUSEA; NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 1942421654     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.12.023     Document Type: Article

References (53)

1. Roila F., Ciccarese G., Paliadino M.A., Angelis V.D. Prevention of radiotherapy-induced emesis. Tumori. 84:1998;274-278.
2. Feyer P.C., Stewart A.L., Titbach O.J. Aetiology and prevention of emesis induced by radiotherapy. Support Cancer Care. 6:1998;253-260.
3. Gralla R.J., Osoba D., Kris M.G.et al. Recommendaions for the use of antiemetics. evidence-based, clinical practice guidelines J. Clin. Oncol. 17:1999;2971-2994.
4. Danjeoux C.E., Rider W.D., Fitzpatrick P.J. The acute radiation syndrome. A memorial to William Michael Court-Broun. Clin. Radiol. 30:1979;581-584.
5. Italian Group for Antiemetic Research in Radiotherapy Radiation-induced emesis. a prospective observational multicenter Italian trial Int. J. Radiat. Oncol. Biol. Phys. 44:1999;619-625.
6. Franzén L., Nyman J., Hagberg H.et al. A randomized placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann. Oncol. 7:1996;587-592.
7. Lawrence C.C., Gilbert C.J., Peters W.P. Evaluation of symptom distress in a bone marrow transplant outpatient environment. Ann. Pharmacother. 30:1996;941-945.
8. Henriksson R., Lomberg H., Israelsson G., Zackrisson B., Franzén L. The effect of ondansetron on radiation-induced emesis and diarrhoea. Acta Oncol. 31:1992;767-769.
9. Yancik R., Ries L.A.G. Aging and cancer in America. Hematol. Oncol. Clin. North Am. 14:2000;17-23.
10. MASCC Prevention of chemotherapy- and radiotherapy-induced emesis. results of the Perugia Consensus Conference Ann. Oncol. 9:1998;811-819.
11. Lanciano R., Sherman D.M., Michalski J., Preston A.J., Yocom K., Friedmanm C. The efficacy and safety of once-daily Kytril® (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest. 19:2001;763-772.
12. Aapro M. Radiotherapy and drugs. 'setrons' once again. Editorial Ann. Oncol. 7:1996;553-554.
13. Bey P., Wilkinson P.M., Resbeut M.et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 4:1996;378-383.
14. Fauser A.A., Russ W., Bischoff M. Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Support Care Cancer. 5:1997;219-222.
15. 3-receptor antagonist, in the prevention of radiation-induced nausea, vomiting and diarrhoea. Drugs. 43(Suppl. 3):1992;33-39.
16. Miralbell R., Coucke P., Behrouz F.et al. Nausea and vomiting in fractionated radiotherapy. a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide Eur J Cancer. 31A:1995;1461-1464.
17. Prentice H.G., Cunningham S., Gandhi L., Cunningham J., Collis C., Hamon M.D. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant. 15:1995;445-448.
18. Sykes A.J., Kiltie A.E., Stewart A.L. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting. a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy Support Care Cancer. 5:1997;500-503.
19. Spitzer T.R., Friedman C.J., Bushnell W., Frankel S.R., Raschko J. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant. 26:2000;203-210.
20. Koriech O.M. Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients. Clin. Oncol. 7:1995;371-372.
21. Stanford B.J., Stanford S.C. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine. J. Psychopharmacol. 13:1999;313-317.
22. Hayes E. Cytochrome P450. Available at: http://www.anaesthetist.com/ physiol/basics/metabol/cyp/o.htm (accessed October 2003).
23. Cagnoni P.J., Matthes S., Day T.C., Bearman S.I., Shpall E.J., Jones R.B. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant. 24:1999;1-4.
24. Gilbert C.J., Petros W.P., Vredenburgh J.et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother. Pharmacol. 42:1998;497-503.
25. Karas S. Jr. The potential for drug interactions. Ann. Emerg. Med. 10:1981;627-630.
26. Adams M.J., Hardenbergh P.H., Constine L.S., Lipshultz S.E. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol. 45:2003;55-75.
27. Biller H., Koop E.A., Prignitz R. [ECG-changes following postoperative irradiation of patients with mammary carcinoma (author's transl)]. Strahlentherapie. 155:1979;541-548.
28. Smets E.M., Visser M.R., Willems-Groot A.F.et al. Fatigue and radiotherapy. (A) experience in patients undergoing treatment Br. J. Cancer. 78:1998;899-906.
29. Jacobsen P.B., Thors C.L. Fatigue in the radiation therapy patient. current management and investigations Semin. Radiat. Oncol. 13:2003;372-380.
30. 3 receptor antagonist. correlation with anti-emetic response Cancer Chemother. Pharmacol. 24:1989;45-49.
31. 3 receptor blockade? Br. J. Cancer. 86:2002;1662-1663.
32. Yancik R., Ganz P.A., Varricchio C.G., Conley B. Perspectives on comorbidity and cancer in older patients. approaches to expand the knowledge base J. Clin. Oncol. 19:2001;1147-1151.
33. Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer. 80:1997;1273-1283.
34. Jörgensen T., Johansson S., Kennerfalk A., Wallander M.A., Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann. Pharmacother. 35:2001;1004-1009.
35. Gridelli C., Perrone F., Gallo C.et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J. Natl. Cancer Inst. 95:2003;362-372.
36. Ashkanani F., Heys S.D., Eremin O. The management of cancer in the elderly. J. R. Coll. Surg. Edinb. 44:1999;2-10.
37. Angelino A.F., Treisman G.J. Major depression and demoralization in cancer patients. diagnostic and treatment considerations Support Care Cancer. 9:2001;344-349.
38. 3 receptors. Neuropharmacology. 32:1993;729-735.
39. 3 receptor antagonists. are they all the same? Cancer Today. (Suppl. 1):2002;14.
40. Anzemet® (dolasetron mesylate) Prescribing Information. 2000;Aventis Pharmaceuticals Inc, Kansas City, MO, USA.
41. Kytril® (granisetron hydrochloride) Prescribing Information. 2000;Roche Laboratories Inc, Nutley, New Jersey, USA.
42. Zofran® (ondansetron hydrochloride) Prescribing Information. 2001;Research Triangle Park, NC, USA.
43. Navoban® Product Information:1997;Novartis Pharmaceuticals Ltd, North Ryde NSW, Australia.
44. Audhuy B., Cappelaere P., Martin M.et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur. J. Cancer. 32A:1996;807-813.
45. Lifsey D.S., Gralla R.J., Clark R.A., Kline R.C. Electrocardiographic changes with serotonin antagonist antiemetics. rate of occurrence and clinical relevance Proc. Am. Soc. Clin. Oncol. 12:1993;463. (abstr 1611).
46. Boike S.C., Ilson B., Zariffa N.et al. Cardiovascular effects of i.v. Granisetron at two administration rates and of ondansetron in healthy adults. Am. J. Health Syst. Pharm. 54:1997;1172-1176.
47. Davis M.P., Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer. 9:2001;442-451.
48. Ma M.K., Woo M.H., McLeod H.L. Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59:2002;2061-2069.
49. Kaiser R., Sezer O., Papies A.et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol. 20:2002;2805-2811.
50. 3-receptor antagonists and the cytochrome P450 system. clinical implications Cancer J. 8:2002;405-414.
51. Emend® prescribing information:2003;Merck & Co., Inc, Whitehouse Station, New Jersey.
52. Blum R.A., Majumdar A., McCrea J.et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. Ther. 25:2003;1407-1419.
53. Cramer J.A. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging. 12:1998;7-15.